psilocybin ↔ treatment-resistant depression

Relations (1)

related 13.00 — strongly supporting 13 facts

Psilocybin is identified as a therapeutic agent for treatment-resistant depression [1], with clinical research by Roseman et al. demonstrating its efficacy [2] and specific neurobiological effects on the amygdala during treatment [3].

Facts (13)

Sources

Neuroimaging in psychedelic drug development: past, present, and ... nature.com Nature 6 facts

claimThe first open-label study of psilocybin for treatment-resistant depression showed that changes in cerebral blood flow in the amygdala, measured with arterial spin-labelling MRI, correlated with changes in depression scores.

referenceCarhart-Harris et al. (2017) used fMRI to measure brain mechanisms associated with the use of psilocybin for treatment-resistant depression.

claimResearch on the cohort from the first open-label psilocybin study for treatment-resistant depression found increased amygdala responses to emotional stimuli, that changes in amygdala connectivity predict some clinical outcomes, and that patients show increased brain response to music stimuli following treatment.

claimPatients with treatment-resistant depression treated with psilocybin showed differences in the functional connectivity of the medial pre-frontal cortex and hippocampus.

referenceCarhart-Harris et al. (2016) conducted an open-label feasibility study on the use of psilocybin with psychological support for treatment-resistant depression.

referenceRoseman et al. (2018) observed increased amygdala responses to emotional faces in patients after receiving psilocybin for treatment-resistant depression.

Psychedelics, Sociality, and Human Evolution frontiersin.org Frontiers 2 facts

referenceR. Watts, C. Day, J. Krzanowski, and R. Carhart-Harris (2017) documented patients' accounts of increased 'connectedness' and 'acceptance' following psilocybin treatment for treatment-resistant depression.

measurementPatients with treatment-resistant depression (n=20) exhibited decreased disconnection, decreased avoidance of difficult emotions, and increased acceptance following psilocybin administration in a 2017 study.

Ancient Roots of Today's Emerging Renaissance in ... link.springer.com Springer 2 facts

referenceRosalind Watts, Camilla Day, Jacob Krzanowski, David J. Nutt, and Robin Carhart-Harris reported in 2017 that patients experienced increased feelings of 'connectedness' and 'acceptance' following psilocybin treatment for treatment-resistant depression.

referenceLeor Roseman, David J. Nutt, and Robin Carhart-Harris published 'Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression' in Frontiers of Pharmacology in 2018.

Psychedelics and Consciousness: Distinctions, Demarcations, and ... ouci.dntb.gov.ua David B Yaden, Matthew W Johnson, Roland R Griffiths, Manoj K Doss, Albert Garcia-Romeu, Sandeep Nayak, Natalie Gukasyan, Brian N Mathur, Frederick S Barrett · Oxford University Press 1 fact

claimLeor Roseman et al. observed increased amygdala responses to emotional faces after psilocybin treatment for treatment-resistant depression, published in Neuropharmacology, volume 142, page 263.

The Causal Role of Consciousness in Psychedelic Therapy for ... pubs.acs.org ACS Publications 1 fact

claimPsychedelic substances, particularly psilocybin, possess therapeutic potential for the treatment of treatment-resistant depression.

Classification Schemes of Altered States of Consciousness - ORBi orbi.uliege.be ORBi 1 fact

claimRoseman et al. (2017) found that the quality of the acute psychedelic experience predicts the therapeutic efficacy of psilocybin for treatment-resistant depression.